Showing results (271-280 of 319) with videos related to

Sort By:
Pageof 32
JAAD International|November 24, 2021
The Personalised Acne Care Pathway-Recommendations to guide longitudinal management from the Personalising Acne: Consensus of ExpertsJerry Tan, Andrew Alexis, Hilary Baldwin, et al.
JAAD International|November 24, 2021
Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panelJerry Tan, Andrew Alexis, Hilary Baldwin, et al.
Dermatology Online Journal|October 31, 2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panelAngela Rosenberg, Danny Zakria, Lauren DeBusk, et al.
International Journal of Dermatology|April 29, 2024
Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentationAndrew Alexis, James Q Del Rosso, Seth Forman, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|December 21, 2018
ParabensAnthony F Fransway, Paulina J Fransway, Donald V Belsito, et al.
Dermatology and Therapy|January 19, 2026
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt StudyJonathan I Silverberg, Lindsay Ackerman, Jerry Bagel, et al.
American Journal of Clinical Dermatology|July 15, 2025
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable StudyAndrew Alexis, Ali Moiin, Jill Waibel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Pageof 32